RT Journal Article
SR Electronic
T1 Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 841
OP 844
DO 10.2967/jnumed.110.084236
VO 52
IS 6
A1 Helmut R. Maecke
A1 Jean Claude Reubi
YR 2011
UL http://jnm.snmjournals.org/content/52/6/841.abstract
AB Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [111In-diethylenetriaminepentaacetic acid0]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as 68Ga, 64Cu, and 18F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with 90Y and 177Lu.